Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.85 |
| ▸ | PGR | P06401 | 3/20 | 0.85 |
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | AR | P10275 | 2/20 | 0.85 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | APEX1 | P27695 | 1/20 | 0.85 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.85 |
| ▸ | IKBKB | O14920 | 1/20 | 0.85 |
| ▸ | CHUK | O15111 | 1/20 | 0.85 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.85 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.85 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.85 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clobetasol SCHEMBL1651129 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL8602501 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL7616575 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL3996 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL13046611 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL30915305 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL19327129 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL5034390 | 1.00 | NR3C1 (0.85) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Clobetasol SCHEMBL28167282 | 0.99 | NR3C1 (0.83) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 | |
| Dexamethasone SCHEMBL20770143 | 0.97 | HIF1A (0.92) | NR3C1CYP3A4HIF1AHSD17B10NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | claimed |
| EP-3665294-B1 | GENETICALLY MODIFIED CANDIDA MALTOSA FOR THE PRODUCTION OF DICARBOXYLIC FATTY ACIDS | NOVAMONT SPA (IT) | 2024-10-23 | — | — | EP | disclosed |
| US-11786492-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | NOVALEAD PHARMA INC (US) | 2023-10-17 | — | — | US | disclosed |
| EP-1680076-B1 | PHARMACEUTICAL AND COSMETIC FORMULATIONS FOR TREATING FINGERNAILS | BIOEQUAL AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| US-20070166249-A1 | Pharmaceutical and cosmetic formulations for treating fingernails | BIOEQUAL AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| EP-1143950-B1 | TOPICAL APPLICATION PRODUCTS AGAINST ONYCHOMYCOSES | BIOEQUAL AG (CH) | 2005-03-09 | — | — | EP | disclosed |
| US-6740326-B1 | WATER-FREE TOPICAL APPLICATION COMPOSITION FOR TREATMENT OF NAIL DISEASES AND NAIL CARE CONSISTING OF ANTIMYCOTIC AGENT AND LOWER ALKYL ESTER OF LACTIC ACID, MALIC ACID, TARTARIC ACID OR CITRIC ACID AS PENETRATION PROMOTING CARRIER | BIOEQUAL AG (CH) | 2004-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885CYP3A4 2529/4885HIF1A 1076/4885 |
| US-11786492-B2 | Therapeutic agent for phosphodiesterase inhibition and its related disorders | PDE3A, PDE9A, PDE12 | NR3C1 2256/4885CYP3A4 300/4885HIF1A 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.